Spedding M, Paoletti R
Department of Pharmacology, Syntex Research Centre, Riccarton, Edinburgh, Scotland.
Cardiovasc Drugs Ther. 1992 Feb;6(1):35-9. doi: 10.1007/BF00050915.
The molecular biology and electrophysiology of calcium channels is proceeding apace, partially driven by the clinical success of the drugs classed as "calcium antagonists." Indeed, there are now more than 70 drugs in development that have been claimed to be "calcium antagonists" of one type or another. In order to ensure that there is a logical nomenclature for the channels and the drugs acting at the channels, an international committee has met over the last 2 years to classify the channels and the drugs. This report consists of an overview of current thinking, which will be finalized in a document submitted to the IUPHAR (International Union of Pharmacologists) nomenclature committee.
钙通道的分子生物学和电生理学正在迅速发展,部分原因是被归类为“钙拮抗剂”的药物在临床上取得了成功。事实上,目前有70多种正在研发的药物被宣称属于某种类型的“钙拮抗剂”。为了确保对通道以及作用于这些通道的药物有一个合理的命名法,一个国际委员会在过去两年里召开会议,对通道和药物进行分类。本报告概述了当前的思路,将在提交给国际药理学联合会(IUPHAR)命名委员会的一份文件中最终确定。